AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03899337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100mg capsule, PO, BD
Study NCT03899337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/m\^2, IV bolus
Study NCT03899337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750mg/m\^2, IV bolus
Study NCT03899337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50mg/m\^2, IV bolus
Study NCT03899337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50mg/m\^2, IV bolus
Study NCT03899337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4mg/m\^2, IV infusion
Study NCT03899337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4mg/m\^2, IV infusion
Study NCT03899337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 40mg/m\^2, PO, OD
Study NCT03899337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 40mg/m\^2, PO, OD
Study NCT01718769 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire STAMP
Description: Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
Study NCT01718769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire STAMP
Description: Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
Study NCT03899337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m\^2, IV infusion
Study NCT03899337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/m\^2, IV infusion
Study NCT00417937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelaic acid 15% gel
Description: 15% gel, topically applied once daily for six weeks
Study NCT00417937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelaic acid 15% gel
Description: 15% gel, topically applied twice daily for six weeks
Study NCT01925079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Education
Description: Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.~Patient education:~1. Routine education at discharge.~2. 4 education brochures will be delivered to patients.~3. Calendar with healthy tips will be delivered to patients before discharge.~4. A follow-up brochure with medical expert letter.~5. A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).~6. Telephone follow ups will be performed according to a standard communication document.~At discharge, patients will be given a brochure for future follow up.
Study NCT01925079 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.~Patient education:~1. Routine education at discharge.~2. A follow-up brochure without medical expert letter.~At discharge, patients will be given a brochure for future follow up.
Study NCT01015742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem cell Transplantation
Description: Busulfan: 3.2 mg/kg IV daily on days -7 to -4~Cyclophosphamide : 60 mg/m² daily on days -3 to -2~Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2~Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90~Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant.
Study NCT02345057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Study NCT02345057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT02345057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT05224791 — intervention group
Intervention type: PROCEDURE
Intervention: Roux-en-Y Gastric Bypass
Description: The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.
Study NCT02607761 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Video-Audio Media
Study NCT02607761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Video-Audio Media
Study NCT05224791 — intervention group
Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy
Description: The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption
Study NCT00005776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: Inhaled Nitric oxide at a concentration of 20 ppm
Study NCT00005776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100% Oxygen
Study NCT01951430 — intervention group
Intervention type: DRUG
Intervention: Antibiotic and antifungal drugs
Study NCT02123693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Study NCT02123693 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy
Study NCT02123693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Study NCT03607448 — intervention group
Intervention type: DEVICE
Intervention: Freestyle Libre Flash Glucose Monitoring System
Description: Subjects will wear the Abbott Sensor based FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes
Study NCT02302729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrients
Description: Nutrient Quantity Nutrient Quantity Zinc 9 mg Copper 0.3 mg Iron 12.5 mg Vitamin D3 5 mg Folic Acid 160 mcg Vitamin E 5 mg Iodine 90 mcg Calcium 200 mg Vitamin A 250 mg Phosphorus 150 mg Vitamin C 40 mg Magnesium 40 mg Vitamin B12 0.9 mcg Selenium 17 mcg Thiamine 0.5 mg Manganese 0.17 mg Niacin 0.5 mg Biotin 8 mg Riboflavin 6 mg Vitamin B5 1.8 mg Vitamin B6 0.5 mg
Study NCT02302729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsive feeding
Description: Strategy~Mother ensures that feeding area is set up with infant and mother able to see one another.~Mother mirrors the infant's facial expressions to attract the infant's attention.~Mother interprets infant's behavior with a positive voice, Oh, you like the spinach. Mother extends infant's behavior by saying, Oh the cereal is all gone and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil
Study NCT02302729 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Responsive feeding
Description: Strategy~Mother ensures that feeding area is set up with infant and mother able to see one another.~Mother mirrors the infant's facial expressions to attract the infant's attention.~Mother interprets infant's behavior with a positive voice, Oh, you like the spinach. Mother extends infant's behavior by saying, Oh the cereal is all gone and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil
Study NCT02302729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Riboflavin Vitamin B2
Study NCT01895166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-GS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
Study NCT01895166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-GS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
Study NCT01895166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
Study NCT01850680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT03282071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joyful Parenting Intervention
Description: * Two-session interactive talks for parents to promote praise \& appreciation, positive thinking, enjoyable parenting (mind) and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~* One family gathering activity (e.g. outdoor / visit / family indoor gathering) to promote and practise quality family communication (enjoyment and sharing).
Study NCT02061189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise in a swimming pool during 6 months
Description: 10 patients will undergo a training program of physical exercise in a swimming pool, 3 days per week during 6 months. Each session will last for 20 minutes.
Study NCT03386799 — intervention group
Intervention type: DEVICE
Intervention: E-motion device
Description: Powered assisted Wheelchair with the E-motion device. Outdoor and indoor runs
Study NCT01121497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physostigmine
Description: Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure
Study NCT01850680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT01850680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Pharmaceutical form:capsule Route of administration: oral
Study NCT01850680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Pharmaceutical form:capsule Route of administration: oral
Study NCT01850680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: folic acid
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT01850680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT05150730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi professional care
Description: Participants were instructed to respect their pain threshold during body practice and the evolution of the participants happened gradually and individually. Associated with the practice of exercise, workers received information about their disease, chronic pain, guidelines for daily activities, and the importance of physical exercise. In the second hour, the responsible psychologist addressed issues such as the repercussions of illnesses on the individual's social and affective life, self-esteem, self-image, conformism, and self-indulgence after the illness and prospects for the future. Throughout the program, participants also received informative lectures from other professionals, such as social workers, nurses, and dentists.
Study NCT03879720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscope assisted endotracheal intubation [EAEI]
Description: Endoscope assisted endotracheal intubation \[EAEI\] performed by anesthesiologist with endoscopist assistance.
Study NCT03879720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscope assisted endotracheal intubation [EAEI]
Description: Endoscope assisted endotracheal intubation \[EAEI\] performed by anesthesiologist with endoscopist assistance.
Study NCT03755505 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: obtain samples from sputum, feces and urine
Description: Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
Study NCT03432624 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum MicroRNA-25 detection
Description: The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.\*all arms are given the same intervention.
Study NCT03408158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: same type infusion of main HPA antigen
Description: Compare the differences of platelet count between participants with same type infusion of main HPA antigen and not
Study NCT00966641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Single orally administered dose of 500 mg naproxen
Study NCT00966641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL 3100
Description: Single orally administered dose of PL 3100 (500 mg naproxen)
Study NCT01876823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: es-citalopram
Description: es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.
Study NCT01876823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
Study NCT02738177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 2 tablets of misoprostol (i.e. 400 ug) 4 hrs prior to surgical evacuation high up in the posterior fornix (misoprostol group)
Study NCT02738177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide-5-mononitrate
Description: 2 tablets of Effox (i.e. 40 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (effox group)
Study NCT02738177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol and Isosorbide-5-mononitrate
Description: 1tablets of misoprostol (i.e.200 ug) \& 1 tablets of Effox (i.e. 20 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (combination therapy group)
Study NCT00142480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).
Study NCT00142480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given intravenously once weekly during weeks 1, 2, 4 and 5 on days 1, 8, 22 and 29
Study NCT00142480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously every two weeks during weeks 1, 3 and 5 on days 1, 15 and 29.
Study NCT00142480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Once daily for 5 days (Monday through Friday) for a total of 28 treatments.
Study NCT04639453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Trunk strength with hand-held dynamometer
Description: MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various trunk muscle groups in flexion, extension, and lateral (N).
Study NCT04639453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Balance Assessment in Sitting and Standing test (BASS)
Description: The BASS is a test to assess static and dynamic sitting and standing balance, which has been validated for post-stroke hemiparetic patients. Each test is evaluated by a score from 0 (patient needs external support) to 4 (stable without external help) for static condition and from 0 (no possibility to pick up objects) to 3 (objects picked up without external help) for dynamic condition. The maximal score (sitting, standing, static and dynamic) is 14 points.
Study NCT04639453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Timed Up and Go test
Description: The participant sits on a chair, gets up, walks 3m, makes a half turn in 1m2, walks 3m and comes back to sit on the chair. The time (s) to complete the task is measured.
Study NCT04639453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Functional Reach Test (MFRT)
Description: The MFRT is a dynamic seated balance test that measures the trunk's ability to move forward, to the paretic and non paretic side (cm).
Study NCT04639453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Joint Position sense test (trunk)
Description: The joint positional sense test of the trunk consists in evaluating the positional error of the trunk in the sagittal plane (mm) and in the frontal plane (mm) during a trunk flexion posture (target position).
Study NCT04639453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Unstable sitting in a seesaw
Description: This test evaluates the balance capacities of the subject in an unstable sitting position on a seesaw (mediolateral or anteroposterior instability) with forceplate and phone application using center of pressure variables: total displacement (mm), area (mm2), deltas (mm), mean velocity (mm/s) et maximal velocity (mm/s).
Study NCT03948776 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BodyMetrix body composition ultrasound
Description: Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.
Study NCT03948776 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BodyMetrix body composition ultrasound only
Description: Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. For inpatients currently admitted to the hospital, whole-body DXA imaging cannot be performed, as so the only assessment of body composition will be with the ultrasound.
Study NCT05170373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: Before general anesthesia, ESP block was applied from the T12 vertebra level with 10 ml 0.5% bupivacaine HCL 5 ml 2% lidocaine HCL 5 ml 0.9% isotonic NaCl mixture
Study NCT04287023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individual physical therapy
Description: cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - individual
Study NCT04060641 — intervention group
Intervention type: GENETIC
Intervention: Geneticure for RDN Genetic Panel
Description: This retrospective trial will include the collection of DNA using buccal swabs and the assessment of 22 genotypes for scoring to assess response to renal denervation
Study NCT02626689 — intervention group
Intervention type: OTHER
Intervention: Quality of Life (QOL) questionnaires
Description: Monitoring of FACT-AN, SF-36V2, TransQol, and NTD PRO assessments,
Study NCT02626689 — intervention group
Intervention type: OTHER
Intervention: Healthcare Resource Utilization
Description: Monitoring and reviewing HealthCare Resource Utilization information.
Study NCT04287023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group physical therapy
Description: cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - groups of 10 patients
Study NCT04250272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic lobectomy
Description: Thoracoscopic lobectomy was performed for lung cancer
Study NCT04250272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopic lobectomy
Description: Thoracoscopic lobectomy was performed for lung cancer
Study NCT00170950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1
Description: Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.
Study NCT01664494 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine will be given according to the label text as monotherapy (1250 mg/m\^2 twice daily) or combination therapy (800 to 1000 mg/m\^2 or 1250 mg/m\^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.